TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: 0.25 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 1 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 5 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VPD-737; Assigned to Arm(s): 0.25 mg VPD-737, 1 mg VPD-737, 5 mg VPD-737 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEWING HEALTH Large-scale Real-life Study in Finland
Brief Summary: The purpose of this trial is to determine if by structured telephone based health coaching programme supported by remote monitoring system among type 2 diabetes, coronary artery disease and heart failure patients the investigators are able to improve their quality of life as measured by the SF-36 questionnaire and reduce a value of HbA1c under 6,5 % among those type 2 diabetes patients who had elevated value of HbA1c when recruited.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational website.; Type: EXPERIMENTAL; Interventions: Other: Educational website (in addition to usual care). | Arm Label: Website and interactive platform with telemonitoring.; Type: EXPERIMENTAL; Interventions: Other: Website and interactive platform with telemonitoring. | Intervention Type: OTHER; Name: Educational website (in addition to usual care).; Assigned to Arm(s): Educational website. | Intervention Type: OTHER; Name: Website and interactive platform with telemonitoring.; Assigned to Arm(s): Website and interactive platform with telemonitoring.
B: Arm Label: telerehabilitation group; Type: EXPERIMENTAL; Interventions: Other: home-based telerehabilitation | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: home-based telerehabilitation; Assigned to Arm(s): telerehabilitation group
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Do CHANGE | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Do CHANGE; Assigned to Arm(s): Intervention
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEWING HEALTH Large-scale Real-life Study in Finland
Brief Summary: The purpose of this trial is to determine if by structured telephone based health coaching programme supported by remote monitoring system among type 2 diabetes, coronary artery disease and heart failure patients the investigators are able to improve their quality of life as measured by the SF-36 questionnaire and reduce a value of HbA1c under 6,5 % among those type 2 diabetes patients who had elevated value of HbA1c when recruited.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care
B: Arm Label: Medical group visits; Type: EXPERIMENTAL; Interventions: Other: Diabetes Group Management Visits | Arm Label: Treatment as Usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Group Management Visits; Assigned to Arm(s): Medical group visits
C: Arm Label: EMPOWER-PAR Intervention; Type: EXPERIMENTAL; Interventions: Other: EMPOWER-PAR Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMPOWER-PAR Intervention; Assigned to Arm(s): EMPOWER-PAR Intervention
D: Arm Label: Basal Insulin Initiation Strategy; Type: EXPERIMENTAL; Interventions: Other: Basal Insulin Initiation Strategy | Arm Label: Usual Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Basal Insulin Initiation Strategy; Assigned to Arm(s): Basal Insulin Initiation Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEWING HEALTH Large-scale Real-life Study in Finland
Brief Summary: The purpose of this trial is to determine if by structured telephone based health coaching programme supported by remote monitoring system among type 2 diabetes, coronary artery disease and heart failure patients the investigators are able to improve their quality of life as measured by the SF-36 questionnaire and reduce a value of HbA1c under 6,5 % among those type 2 diabetes patients who had elevated value of HbA1c when recruited.


Options:
A: Arm Label: iHEART; Type: EXPERIMENTAL; Interventions: Device: AliveCor, Behavioral: Behavioral Altering Messaging | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: AliveCor; Assigned to Arm(s): iHEART | Intervention Type: BEHAVIORAL; Name: Behavioral Altering Messaging; Assigned to Arm(s): iHEART
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prevention Consult; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prevention Consult | Arm Label: Consult & Behavioral Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Consult & Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Prevention Consult; Assigned to Arm(s): Prevention Consult | Intervention Type: BEHAVIORAL; Name: Consult & Behavioral Intervention; Assigned to Arm(s): Consult & Behavioral Intervention
C: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Therapy for Acute Gout: Does Initial Use of Allopurinol Effect Duration and/or Recurrence Rate of Acute Attacks
Brief Summary: Medical teaching suggests allopurinol should not be initiated in the setting of an acute attack of gout, as rapid lowering of serum urate may exacerbate the attack. This study tests the hypothesis that there is no difference in patient reported daily pain or flair occurrences with early versus delayed institution of allopurinol during an acute gout attack.


Options:
A: Arm Label: Allopurinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 120 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 240 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
C: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (for Rilonacept) | Arm Label: Rilonacept 160 mg; Type: EXPERIMENTAL; Interventions: Biological: Rilonacept | Intervention Type: BIOLOGICAL; Name: Rilonacept; Assigned to Arm(s): Rilonacept 160 mg | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Randomized, Double-Blind Phase II Study Comparing Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo in Subjects With Recurrent/Progressive Glioblastoma (DORIC Trial)
Brief Summary: RATIONALE: Cediranib Maleate and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether cediranib maleate given together with gefitinib is more effective than cediranib maleate given alone in treating patients with recurrent or progressive glioblastoma.

PURPOSE: This randomized phase II trial is studying the side effects of giving cediranib maleate together with gefitinib and to see how well it works compared with giving cediranib maleate together with a placebo in treating patients with recurrent or progressive glioblastoma.


Options:
A: Arm Label: Group A: DNX-2401; Type: EXPERIMENTAL; Interventions: Drug: DNX-2401 | Arm Label: Group B: DNX-2401 + Surgery; Type: EXPERIMENTAL; Interventions: Drug: DNX-2401, Procedure: Tumor Removal | Intervention Type: DRUG; Name: DNX-2401; Assigned to Arm(s): Group A: DNX-2401, Group B: DNX-2401 + Surgery | Intervention Type: PROCEDURE; Name: Tumor Removal; Assigned to Arm(s): Group B: DNX-2401 + Surgery
B: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
C: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
D: Arm Label: Carbon Ion Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Carbon Ion Radiotherapy | Arm Label: Standard Treatment: Fractionated Stereotacitc Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Fractionated Stereotactic Radiotherapy (FSRT) | Intervention Type: RADIATION; Name: Carbon Ion Radiotherapy; Assigned to Arm(s): Carbon Ion Radiotherapy | Intervention Type: RADIATION; Name: Fractionated Stereotactic Radiotherapy (FSRT); Assigned to Arm(s): Standard Treatment: Fractionated Stereotacitc Radiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Randomized, Double-Blind Phase II Study Comparing Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo in Subjects With Recurrent/Progressive Glioblastoma (DORIC Trial)
Brief Summary: RATIONALE: Cediranib Maleate and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether cediranib maleate given together with gefitinib is more effective than cediranib maleate given alone in treating patients with recurrent or progressive glioblastoma.

PURPOSE: This randomized phase II trial is studying the side effects of giving cediranib maleate together with gefitinib and to see how well it works compared with giving cediranib maleate together with a placebo in treating patients with recurrent or progressive glioblastoma.


Options:
A: Arm Label: Calibration Arm; Type: EXPERIMENTAL; Interventions: Drug: fotemustine | Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: fotemustine; Assigned to Arm(s): Calibration Arm
B: Arm Label: 5-aminolevulinic acid; Type: EXPERIMENTAL; Interventions: Drug: 5-aminolevulinic acid (5-ALA) | Arm Label: Conventional resection; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-aminolevulinic acid (5-ALA); Assigned to Arm(s): 5-aminolevulinic acid
C: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
D: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Randomized, Prospective Trial of Impact of Pain Scores on Intrauterine Lidocaine vs Normal Saline Infusion Before IUD Placement.
Brief Summary: The study hypothesis is that infusion of 2% lidocaine at the time of IUD placement will reduce pain scores related to that procedure. In a double blinded randomized trial of 60 women receiving either normal saline or lidocaine infused through an endometrial aspirator, pain scores will be obtained for each step of the IUD placement procedure and for the total experience.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: 2% lidocaine gel | Intervention Type: DRUG; Name: 2% lidocaine gel; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): Control Group
C: Arm Label: 2% Lidocaine liquid; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): 2% Lidocaine liquid | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline
D: Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Simplified Tai Chi for Reducing Fibromyalgia Pain
Brief Summary: Data from two recent Tai chi studies have found that Tai Chi yields symptomatic benefit in patients with fibromyalgia (FM). The purpose of this study is to confirm those findings in a larger randomized, controlled clinical trial in a community-based setting. We also sought to extend this line of inquiry by closely examining Tai chi's effect on physical function, specifically postural stability. Towards these ends, we conducted a single-blind, randomized controlled clinical trial of an FM modified 8-form Yang-style Tai chi program compared to standard education. Subjects in both conditions meet in small groups two times weekly for 60 minutes over 12 weeks.


Options:
A: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group
B: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle physical activity (LPA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fibromyalgia education | Intervention Type: BEHAVIORAL; Name: Lifestyle physical activity (LPA); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Fibromyalgia education; Assigned to Arm(s): 2
D: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Simplified Tai Chi for Reducing Fibromyalgia Pain
Brief Summary: Data from two recent Tai chi studies have found that Tai Chi yields symptomatic benefit in patients with fibromyalgia (FM). The purpose of this study is to confirm those findings in a larger randomized, controlled clinical trial in a community-based setting. We also sought to extend this line of inquiry by closely examining Tai chi's effect on physical function, specifically postural stability. Towards these ends, we conducted a single-blind, randomized controlled clinical trial of an FM modified 8-form Yang-style Tai chi program compared to standard education. Subjects in both conditions meet in small groups two times weekly for 60 minutes over 12 weeks.


Options:
A: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
B: Arm Label: placebo (P); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: phototherapy (FT); Type: EXPERIMENTAL; Interventions: Radiation: Group Phototherapy | Arm Label: phototherapy+Physical activity (FT+A); Type: EXPERIMENTAL; Interventions: Radiation: Phototherapy + Physical activity | Arm Label: Physical activity (A); Type: EXPERIMENTAL; Interventions: Other: Physical activity | Intervention Type: RADIATION; Name: Group Phototherapy; Assigned to Arm(s): phototherapy (FT) | Intervention Type: RADIATION; Name: Phototherapy + Physical activity; Assigned to Arm(s): phototherapy+Physical activity (FT+A) | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity (A) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo (P)
C: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength training | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise
D: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education

Answer: D